• Tesla opens patents: What's Musk's end game?     Thursday, 12 Jun 2014 | 3:24 PM ET

    Tesla CEO Elon Musk has announced it is opening up all its patents to competitors to spur innovation. CNBC's Phil LeBeau has the details.

  • DETROIT, June 12- Tesla Motors Inc on Thursday said it would allow others to use its intellectual property in hopes of speeding up development of electric cars by all manufacturers. Tesla co-founder and Chief Executive Officer Elon Musk said the company would not take legal action against anyone who "in good faith, wants to use our technology."

  • Elon Musk opens Tesla's patents     Thursday, 12 Jun 2014 | 1:05 PM ET

    CNBC's Phil LeBeau reports Tesla CEO Elon Musk has announced the automaker will open up its patents to spur innovation in the auto industry.

  • SAN FRANCISCO, June 10- Patent risk management company RPX Corp is in advanced talks to acquire litigation data provider PatentFreedom, three sources familiar with the deal said, a move that highlights the growing importance of services for companies trying to fend off patent lawsuits.

  • Patent system not broken: Inventergy CEO     Tuesday, 10 Jun 2014 | 8:40 AM ET

    Patents help spur innovation and competitiveness in the U.S., says Joe Beyers, Inventergy chairman and CEO.

  • Business of IP patents     Tuesday, 10 Jun 2014 | 8:37 AM ET

    Joe Beyers, Inventergy chairman and CEO, shares the company's business model and reasons for going public.

  • Why Merck's Idenix deal is bad news for Gilead Monday, 9 Jun 2014 | 2:34 PM ET

    Analysts say there's more to Merck's interest in Idenix than its drug portfolio: intellectual property. And that's why Gilead's shares are lower.

  • Revolution coming to biology: CEO     Friday, 6 Jun 2014 | 11:33 AM ET

    "What happened in electronics and software is about to happen in biology," says Jay Walker, Patent Properties chairman, discussing the impending explosion in the health and wellness sector. Walker also explains how Apple's "HealthKit" may be paving the way towards a market with tech driven, individualized health care.

  • WASHINGTON, June 2- The U.S. Supreme Court on Monday overturned two lower court patent decisions, one related to heart rate monitors and the other to management of Web images, in rulings that could make it harder for so-called patent trolls to win infringement cases.

  • WASHINGTON, June 2- The U.S. Supreme Court threw out two patent decisions on Monday, one related to heart rate monitors and the other on management of web images, rulings that could make it harder for patent trolls to win infringement cases.

  • Over-the-counter Cialis?     Wednesday, 28 May 2014 | 2:16 PM ET

    CNBC's Meg Tirrell reports Sanofi and Eli Lilly announced an agreement to pursue regulatory approval of an over-the-counter version of erectile dysfunction drug Cialis.

  • May 20- Medtronic Inc agreed to pay royalties to rival Edwards Lifesciences Corp so it can continue to sell its CoreValve replacement heart valves, the medical device maker said on Tuesday. Medtronic said it would give Edwards a one-time payment of $750 million, plus ongoing royalty payments through April 2022, based on a percentage of CoreValve sales.

  • May 20- Medtronic Inc said on Tuesday it agreed to pay royalties to rival medical device maker Edwards Lifesciences Corp in a settlement that allows Medtronic to continue to sell its CoreValve replacement heart valves.

  • SAN FRANCISCO, May 16- Apple Inc and Google Inc's Motorola Mobility unit have agreed to settle all patent litigation between them over smartphone technology, ending one of the highest profile lawsuits in technology. "Apple and Google have also agreed to work together in some areas of patent reform," the statement said.

  • How not to fear biotech     Thursday, 15 May 2014 | 1:24 PM ET

    Discussing hot picks in the biotech space, with Matthew Roden, UBS executive director.

  • Eli Lilly loses UK Alimta patent case to Actavis Thursday, 15 May 2014 | 7:07 AM ET

    LONDON, May 15- Eli Lilly said on Thursday it had lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis.

  • WASHINGTON, May 14- A U.S. appeals court on Wednesday affirmed a decision by the International Trade Commission that Apple Inc was innocent of violating three patents owned by Samsung Electronics to make its iPhones and iPads. The ITC had said in June 2013 that Apple did not infringe on the Samsung patents.

  • Will the U.S. patent bill regain its momentum? Monday, 12 May 2014 | 6:23 PM ET

    WASHINGTON, May 12- After flying through the U.S. House of Representatives and winning the support of an influential senator, closely watched legislation aimed at reducing frivolous patent litigation appears to have stalled, at least for now.

  • *Vivus has 7 U.S. patents for Qsymia, earliest expires in June 2020. May 9- Vivus Inc said on Friday drugmaker Actavis Plc plans to market a generic version of Vivus's obesity drug Qsymia that was approved in July 2012.

  • Apple vs. Samsung: Who wins?     Tuesday, 6 May 2014 | 1:41 PM ET

    The epic patent fight between Samsung and Apple ended on Monday after a jury ordered Samsung pay $120 million in damages for copying iPhone technology. Kurt Eichenwald, Vanity Fair, profiled the mobile giants in the June issue.